Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources.

In vitro drug metabolism techniques with human CYP c-DNA expressed systems are frequently used to predict human drug metabolism in vivo. The aim of this study was to compare midazolam enzyme kinetics in recombinant expressed CYP3A4 microsomes from human and insect cells. The amounts of 1'- hydroxymidazolam and 4-hydroxymidazolam formed in CYP3A4 microsomes from transfected human liver epithelial cells (T5-3A4 microsomes) and baculovirus-infected insect cells (with and without coexpressed cytochrome b(5)) were analysed by LC-MS. Enzyme kinetic parameters were estimated by nonlinear regression. Mean K(m) for the formation of 1'-hydroxymidazolam was 3- and 4-fold higher in T5-3A4 microsomes than in insect microsomes (p<0.05), with and without coexpressed cytochrome b(5), respectively. Only minor differences in V(max) were observed and the higher K(m) in T5-3A4 microsomes was reflected by significantly lower Cl(int) compared to insect microsomes (p<0.001). For formation of 1'-hydroxymidazolam, human microsomes displayed Michaelis-Menten kinetics, while insect microsomes showed substrate inhibition kinetics. The different enzyme kinetics of midazolam observed in recombinant CYP3A4 microsomes from human and insect sources, especially the substantially higher K(m) obtained in human microsomes compared to insect microsomes, should be further evaluated since it may have implications for correlations to in vivo situation.

[1]  H. Yamazaki,et al.  Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes , 2007, Drug Metabolism and Disposition.

[2]  C. Emoto,et al.  Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: The effect of the expression of cytochrome b5 with recombinant P450 enzymes , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  C. Emoto,et al.  Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1′-hydroxylation , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  Mary F Paine,et al.  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.

[5]  R. Riley,et al.  Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5 , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  E. Molden,et al.  Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design. , 2006, Current drug metabolism.

[7]  C. Emoto,et al.  Enzymatic characteristics of CYP3A5 and CYP3A4: A comparison of in vitro kinetic and drug–drug interaction patterns , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  J B Houston,et al.  Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  Weili Huang,et al.  EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM , 2004, Drug Metabolism and Disposition.

[10]  Aleksandra Galetin,et al.  UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES , 2004, Drug Metabolism and Disposition.

[11]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  H. Yamazaki,et al.  Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. , 2003, Biochemical pharmacology.

[13]  D. Greenblatt,et al.  In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[14]  T. Christoffersen,et al.  Role of ERK, p38 and PI3-kinase in EGF Receptor-Mediated Mitogenic Signalling in Cultured Rat Hepatocytes: Requirement for Sustained ERK Activation , 2003, Cellular Physiology and Biochemistry.

[15]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[16]  T. Tracy,et al.  Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[17]  J. Houston,et al.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[18]  J S Harmatz,et al.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[19]  J B Houston,et al.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[20]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[21]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[22]  C. Harris,et al.  Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. , 1997, Carcinogenesis.

[23]  P. Thomas,et al.  Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[24]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.

[25]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[26]  A. Pfeifer,et al.  Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[28]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.